Skip to main content
Clinical Trials/JPRN-UMIN000017523
JPRN-UMIN000017523
Recruiting
未知

Prospective and Non-interventional registry to Investigate Effectiveness and Safety of Rivaroxaban on Prevention of Stroke and Systemic Embolism in Patients with Non-valvular Atrial Fibrillation at Fukui Red Cross Hospital - Prospective and Non-interventional registry to Investigate pharmacokinetics (for the coagulation/fibrinolysis status and vascular function) and Safety of Rivaroxaban in Patients with Non-valvular Atrial Fibrillation (FENIX Registry)

Fukui Red Cross Hospital0 sites100 target enrollmentMay 12, 2015

Overview

Phase
未知
Intervention
Not specified
Conditions
on-valvular atrial fibrillation (In the present study, non-valvular atrial fibrillation refers to atrial fibrillation without a history of prosthetic valve replacement or mitral valve stenosis.)
Sponsor
Fukui Red Cross Hospital
Enrollment
100
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 12, 2015
End Date
December 31, 2015
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Fukui Red Cross Hospital

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • The following patients in whom rivaroxaban is contraindicated for use \- Patients with a history of allergies to the ingredients contained in this drug \- Patients having a hemorrhagic event (intracranial hemorrhage, gastrointestinal hemorrhage or other clinically significant hemorrhagic events) \- Patients having liver disease complicated with coagulation disorder or those having moderate or worse liver disorder (Grade B or C in accordance with the Child\-Pugh classification) \- Patients having renal failure (creatinine clearance \<15 mL/min) \- Women who are or are likely to be pregnant \- Patients who are treated with HIV protease inhibitors (including ritonavir, atazanavir and indinavir) \- Patients who are treated with oral or injectable formulations of azole antifungal drugs (including itraconazole, voriconazole and ketoconazole (excluding fluconazole)) \-Patients with acute bacterial endocarditis \- Patients have remaining effects are received with other anticoagulation therapy \-Patients are unstable state of blood pressure(18/120mmHg\>)

Outcomes

Primary Outcomes

Not specified

Similar Trials